p53 induces distinct epigenetic states at its direct target promoters
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: The tumor suppressor protein p53 is a transcription factor that is mutated in many cancers. Regulation of gene expression by binding of wild-type p53 to its target sites is accompanied by changes in epigenetic marks like histone acetylation. We studied DNA binding and epigenetic changes induced by wild-type and mutant p53 in non-malignant hTERT-immortalized human mammary epithelial cells overexpressing either wild-type p53 or one of four p53 mutants (R175H, R249S, R273H and R280K) on a wild-type p53 background. Results: Using chromatin immunoprecipitation coupled to a 13,000 human promoter microarray, we found that wild-type p53 bound 197 promoters on the microarray including known and novel p53 targets. Of these p53 targets only 20% showed a concomitant increase in histone acetylation, which was linked to increased gene expression, while 80% of targets showed no changes in histone acetylation. We did not observe any decreases in histone acetylation in genes directly bound by wild-type p53. DNA binding in samples expressing mutant p53 was reduced over 95% relative to wild-type p53 and very few changes in histone acetylation and no changes in DNA methylation were observed in mutant p53 expressing samples. Conclusion: We conclude that wild-type p53 induces transcription of target genes by binding to DNA and differential induction of histone acetylation at target promoters. Several new wild-type p53 target genes, including DGKZ, FBXO22 and GDF9, were found. DNA binding of wild-type p53 is highly compromised if mutant p53 is present due to interaction of both p53 forms resulting in no direct effect on epigenetic marks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551 · cited 4×
“Most common p53 structure mutations appear in codons R175, G245, R249, and R282 [ 24 ].”
BackgroundInfluentialA Global Map of p53 Transcription-Factor Binding Sites in the Human Genome
Wei, C.-L., Wu, Q., Vega, V. B., Chiu, K. P., Ng, P., Zhang, T., Shahab, A., Yong, H. C., Fu, Y., Weng, Z., et al. (2006) · Cell · doi:10.1016/j.cell.2005.10.043 · Cited by 1,141 · cited 3×
“For example, using a DNA sequencing strategy, Wei et al [ 19 ] observed that the p53 binding sites of genes that are transcriptionally activated tend to cluster around the transcriptional start of the gene.”
BackgroundMethodInfluentialBarlev, N. A., Liu, L., Chehab, N. H., Mansfield, K., Harris, K. G., Halazonetis, T. D., & Berger, S. L. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00414-2 · Cited by 710
Di Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, M., Sacchi, A., Blandino, G., & Piaggio, G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.013 · Cited by 418 · cited 1×
“Chromatin immunoprecipitation experiments have shown that mt p53 can bind the promoter regions of genes in vivo; however, efforts to identify mt p53 specific DNA-binding response elements have failed [ 32-34 ].”
BackgroundEspinosa, J. M., Verdun, R. E., & Emerson, B. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00359-9 · Cited by 256 · cited 2×
“In response to various genotoxic stresses, wt p53 binds specific sequence elements in the promoters of its target genes such as p21, MDM2, PUMA, and PCNA [1-8].”
BackgroundNegative regulation of bcl-2 expression by p53 in hematopoietic cells
Wu, Y.-L., Mehew, J. W., Heckman, C. A., Arcinas, M., & Boxer, L. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204067 · Cited by 221 · cited 1×
“Activation of wt p53 also causes repression of a subset of its target genes such as MAP4, AFP, BCL2, survivin, and various cell cycle regulatory genes [9-13].”
BackgroundCharacterization of genome-wide p53-binding sites upon stress response
Smeenk, L., van Heeringen, S. J., Koeppel, M., van Driel, M. A., Bartels, S. J. J., Akkers, R. C., Denissov, S., Stunnenberg, H. G., & Lohrum, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn232 · Cited by 211 · cited 2×
“Previous studies analyzed either only wt p53 binding on a genome wide scale [15,16,18-20] or binding of selected p53 mutants to a few selected p53 target gene promoters [8].”
Background
Research works printed but not linked: 44
- Espinosa JM, Emerson BM: Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol Cell. 2001, 8 (1): 57-69. · DOI · Paper page
- Kaeser MD, Iggo RD: Promoter-specific p53-dependent histone acetylation following DNA damage. Oncogene. 2004, 23 (22): 4007-4013. · DOI
- Lagger G, Doetzlhofer A, Schuettengruber B, Haidweger E, Simboeck E, Tischler J, Chiocca S, Suske G, Rotheneder H, Wintersberger E: The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. Mol Cell Biol. 2003, 23 (8): 2669-2679. · DOI · Paper page
- Liu G, Xia T, Chen X: The activation domains, the proline-rich domain, and the C-terminal basic domain in p53 are necessary for acetylation of histones on the proximal p21 promoter and interaction with p300/CREB-binding protein. J Biol Chem. 2003, 278 (19): 17557-17565. · DOI · Paper page
- Shan B, Xu J, Zhuo Y, Morris CA, Morris GF: Induction of p53-dependent activation of the human proliferating cell nuclear antigen gene in chromatin by ionizing radiation. J Biol Chem. 2003, 278 (45): 44009-44017. · DOI
- Magrini R, Russo D, Fronza G, Inga A, Menichini P: The kinetics of p53-binding and histone acetylation at target promoters do not strictly correlate with gene expression after UV damage. J Cell Biochem. 2007, 100 (5): 1276-1287. · DOI
- Esteve PO, Chin HG, Pradhan S: Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells. J Biol Chem. 2007, 282 (4): 2615-2625. · DOI · Paper page
- Imbriano C, Gurtner A, Cocchiarella F, Di Agostino S, Basile V, Gostissa M, Dobbelstein M, Del Sal G, Piaggio G, Mantovani R: Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters. Mol Cell Biol. 2005, 25 (9): 3737-3751. · DOI · Paper page
- Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ, George DL: Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. 1999, 13 (19): 2490-2501. · DOI · Paper page
- Nguyen TT, Cho K, Stratton SA, Barton MC: Transcription factor interactions and chromatin modifications associated with p53-mediated, developmental repression of the alpha-fetoprotein gene. Mol Cell Biol. 2005, 25 (6): 2147-2157. · DOI · Paper page
- Hoh J, Jin S, Parrado T, Edington J, Levine AJ, Ott J: The p53MH algorithm and its application in detecting p53-responsive genes. Proc Natl Acad Sci USA. 2002, 99 (13): 8467-8472. · DOI · Paper page
- Jen KY, Cheung VG: Identification of novel p53 target genes in ionizing radiation response. Cancer Res. 2005, 65 (17): 7666-7673. · DOI · Paper page
- Krieg AJ, Hammond EM, Giaccia AJ: Functional analysis of p53 binding under differential stresses. Mol Cell Biol. 2006, 26 (19): 7030-7045. · DOI · Paper page
- Miled C, Pontoglio M, Garbay S, Yaniv M, Weitzman JB: A genomic map of p53 binding sites identifies novel p53 targets involved in an apoptotic network. Cancer Res. 2005, 65 (12): 5096-5104. · DOI · Paper page
- Wang L, Wu Q, Qiu P, Mirza A, McGuirk M, Kirschmeier P, Greene JR, Wang Y, Pickett CB, Liu S: Analyses of p53 target genes in the human genome by bioinformatic and microarray approaches. J Biol Chem. 2001, 276 (47): 43604-43610. · DOI · Paper page
- Pavletich NP, Chambers KA, Pabo CO: The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 1993, 7 (12B): 2556-2564. · DOI · Paper page
- Unger T, Nau MM, Segal S, Minna JD: p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J. 1992, 11 (4): 1383-1390. · DOI · Paper page
- Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature. 2000, 408 (6810): 307-310. · DOI · Paper page
- Elledge RM, Allred DC: The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat. 1994, 32 (1): 39-47. · DOI
- Iacopetta B, Grieu F, Powell B, Soong R, McCaul K, Seshadri R: Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer. Clin Cancer Res. 1998, 4 (7): 1597-1602.
- Runnebaum IB, Nagarajan M, Bowman M, Soto D, Sukumar S: Mutations in p53 as potential molecular markers for human breast cancer. Proc Natl Acad Sci USA. 1991, 88 (23): 10657-10661. · DOI · Paper page
- Sjogren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L, Bergh J: The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst. 1996, 88 (3–4): 173-182. · DOI · Paper page
- O'Farrell TJ, Ghosh P, Dobashi N, Sasaki CY, Longo DL: Comparison of the effect of mutant and wild-type p53 on global gene expression. Cancer Res. 2004, 64 (22): 8199-8207. · DOI · Paper page
- Scian MJ, Stagliano KE, Ellis MA, Hassan S, Bowman M, Miles MF, Deb SP, Deb S: Modulation of gene expression by tumor-derived p53 mutants. Cancer Res. 2004, 64 (20): 7447-7454. · DOI · Paper page
- Tepper CG, Gregg JP, Shi XB, Vinall RL, Baron CA, Ryan PE, Desprez PY, Kung HJ, deVere White RW: Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells. Prostate. 2005, 65 (4): 375-389. · DOI · Paper page
- Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M, Rotter V: Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res. 2004, 64 (22): 8318-8327. · DOI · Paper page
- Zalcenstein A, Weisz L, Stambolsky P, Bar J, Rotter V, Oren M: Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53. Oncogene. 2006, 25 (3): 359-369. · DOI
- Junk DJ, Vrba L, Watts GS, Oshiro MM, Martinez JD, Futscher BW: Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells. Neoplasia. 2008, 10 (5): 450-461. · DOI · Paper page
- Soussi T, Rubio-Nevado JM, Hamroun D, Béroud C: The p53 Mutation Handbook. 2007, [http://p53.free.fr]
- Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL, Volkert TL, Schreiber J, Rolfe PA, Gifford DK: Control of pancreas and liver gene expression by HNF transcription factors. Science. 2004, 303 (5662): 1378-1381. · DOI · Paper page
- Nouzova M, Holtan N, Oshiro MM, Isett RB, Munoz-Rodriguez JL, List AF, Narro ML, Miller SJ, Merchant NC, Futscher BW: Epigenomic changes during leukemia cell differentiation: analysis of histone acetylation and cytosine methylation using CpG island microarrays. J Pharmacol Exp Ther. 2004, 311 (3): 968-981. · DOI
- Oshiro MM, Watts GS, Wozniak RJ, Junk DJ, Munoz-Rodriguez JL, Domann FE, Futscher BW: Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression. Oncogene. 2003, 22 (23): 3624-3634. · DOI
- el-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burrell M, Hill DE, Healy E, Rees JL, Hamilton SR: Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res. 1995, 55 (13): 2910-2919.
- Hoeller C, Thallinger C, Pratscher B, Bister MD, Schicher N, Loewe R, Heere-Ress E, Roka F, Sexl V, Pehamberger H: The non-receptor-associated tyrosine kinase Syk is a regulator of metastatic behavior in human melanoma cells. J Invest Dermatol. 2005, 124 (6): 1293-1299. · doi:10.1111/j.0022-202x.2005.23685.x
- Muthusamy V, Duraisamy S, Bradbury CM, Hobbs C, Curley DP, Nelson B, Bosenberg M: Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res. 2006, 66 (23): 11187-11193. · DOI · Paper page
- Toyama T, Iwase H, Yamashita H, Hara Y, Omoto Y, Sugiura H, Zhang Z, Fujii Y: Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer. Cancer Lett. 2003, 189 (1): 97-102. · doi:10.1016/s0304-3835(02)00463-9
- Wang L, Duke L, Zhang PS, Arlinghaus RB, Symmans WF, Sahin A, Mendez R, Dai JL: Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. Cancer Res. 2003, 63 (15): 4724-4730.
- Hanavadi S, Martin TA, Watkins G, Mansel RE, Jiang WG: The role of growth differentiation factor-9 (GDF-9) and its analog, GDF-9b/BMP-15, in human breast cancer. Ann Surg Oncol. 2007, 14 (7): 2159-2166. · doi:10.1245/s10434-007-9397-5
- Los AP, Vinke FP, de Widt J, Topham MK, van Blitterswijk WJ, Divecha N: The retinoblastoma family proteins bind to and activate diacylglycerol kinase zeta. J Biol Chem. 2006, 281 (2): 858-866. · DOI
- Cenciarelli C, Chiaur DS, Guardavaccaro D, Parks W, Vidal M, Pagano M: Identification of a family of human F-box proteins. Curr Biol. 1999, 9 (20): 1177-1179. · DOI · Paper page
- Wozniak RJ, Klimecki WT, Lau SS, Feinstein Y, Futscher BW: 5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene. 2007, 26 (1): 77-90. · DOI · Paper page
- Novak P, Jensen T, Oshiro MM, Wozniak RJ, Nouzova M, Watts GS, Klimecki WT, Kim C, Futscher BW: Epigenetic inactivation of the HOXA gene cluster in breast cancer. Cancer Res. 2006, 66 (22): 10664-10670. · DOI
- Smyth GK: Limma: linear models for microarray data. Bioinformatics and Computational Biology Solutions using R and Bioconductor. Edited by: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W. 2005, New York: Springer, 397-420. · DOI · Paper page
- Fury W, Batliwalla F, Gregersen PK, Li W: Overlapping probabilities of top ranking gene lists, hypergeometric distribution, and stringency of gene selection criterion. Conf Proc IEEE Eng Med Biol Soc. 2006, 1: 5531-5534. · DOI · Paper page
Cited by
Census and evaluation of p53 target genes
Fischer, M. (2017) · Oncogene · doi:10.1038/onc.2016.502 · Cited by 971
Metabolic reprogramming and epigenetic modifications on the path to cancer
Sun, L., Zhang, H., & Gao, P. (2022) · Protein & Cell · doi:10.1007/s13238-021-00846-7 · Cited by 770
Cellular and epigenetic drivers of stem cell ageing
Ermolaeva, M., Neri, F., Ori, A., & Rudolph, K. L. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0020-3 · Cited by 272
Menendez, D., Nguyen, T.-A., Freudenberg, J. M., Mathew, V. J., Anderson, C. W., Jothi, R., & Resnick, M. A. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt504 · Cited by 154
“Previously, H3 and H4 histone acetylation changes were observed for 20% of target genes in human cells when p53 is overexpressed (44) or after 5-fluorouracil treatment (45), whereas different patterns of H3K4 di- and H3K27 tri-methylation were detected in repressed versus activated p53 genes in mouse embryonic stem ce…”
BackgroundThe transcription factor p53: Not a repressor, solely an activator.
Fischer, M., Steiner, L., & Engeland, K. (2014) · Cell Cycle · doi:10.4161/15384101.2014.949083 · Cited by 153
Metadata
- Authors
- Vrba, L., Junk, D. J., Novak, P., & Futscher, B. W.
- Venue
- BMC Genomics
- Published
- 2008-10-15
- Volume
- 9
- Issue
- 1
- Pages
- 486-486
- ISSN
- 1471-2164 (ISSN-L)
- OpenAlex
- W2068907918
- Cited by
- 58
- References
- 7
- FWCI
- 1.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: p53 induces distinct epigenetic states at its direct target promoters. https://app.cochat.ai/papers/10.1186/1471-2164-9-486
- The paper
- Vrba, L., Junk, D. J., Novak, P., & Futscher, B. W. (2008). p53 induces distinct epigenetic states at its direct target promoters. BMC Genomics. https://doi.org/10.1186/1471-2164-9-486
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.